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Despite the high rates of dengue in many tropical des-
tinations frequented by tourists, limited information is avail-
able on the risk for infection among short-term visitors. We
retrospectively surveyed 4,000 persons who arrived in
Hawaii during the peak of the 2001–2002 dengue outbreak
and collected follow-up serologic test results for those
reporting denguelike illness. Of 3,064 visitors who respond-
ed, 94 (3%) experienced a denguelike illness either during
their trip or within 14 days of departure; 34 of these persons
were seen by a physician, and 2 were hospitalized. Twenty-
seven visitors with denguelike illness provided a serum
specimen; all specimens were negative for anti-dengue
immunoglobulin G antibodies. The point estimate of
dengue incidence was zero infections per 358 person-days
of exposure with an upper 95% confidence limit of 3.0
cases per person-year. Thus, the risk for dengue infection
for visitors to Hawaii during the outbreak was low. 
D
engue viruses cause a range of clinical illness, includ-
ing dengue fever, dengue hemorrhagic fever, and
dengue shock syndrome. Dengue is transmitted by infect-
ed Aedes mosquitoes and is endemic in many areas in the
world (1). The occurrence of dengue is rising worldwide,
particularly in the Americas, where the reported incidence
more than tripled from 1996 to 2002 (2).At the beginning
of the 21st century, dengue fever and dengue hemorrhagic
fever are the most important arboviral diseases of humans,
with an estimated 50–100 million dengue fever cases and
several hundred thousand dengue hemorrhagic fever cases
occurring each year (3). 
In September 2001, the Hawaii Department of Health
(HDOH) identified the first autochthonous case of dengue
fever in 56 years. The ensuing dengue virus 1 (DENV-1)
outbreak, transmitted by Aedes albopictus mosquitoes,
spanned 9 months. Atotal of 122 laboratory-positive infec-
tions cases were identified from 3 islands: Maui (n = 92),
Oahu (n = 26, and Kauai (n = 4) (Figure 1). Seven (6%) of
the dengue infections were documented among nonresi-
dents, all of whom had stayed in the Hana area of Maui.
Despite the relatively high rates of dengue in many
tropical destinations frequented by tourists and numerous
case reports of dengue in travelers, limited information is
available on the risk for infection among short-term visi-
tors (4–8). An estimate of 1 case of dengue illness per
1,000 travelers has been reported recently; however, this
figure was derived from surveys of soldiers and expatriates
living abroad, i.e., persons whose exposure risks may be
quite different from those of recreational travelers (9).
Given that Hawaii receives >7 million visitors each year,
even low rates of dengue transmission to visitors during an
outbreak could result in substantial numbers of infections
being exported to the US mainland and elsewhere. We
studied the risk for dengue infection among visitors to
Hawaii during the peak of the outbreak in 2001.
Methods
State law requires passengers and families to submit a
“Plants and Animals Declaration Form” on arrival in
Hawaii. The declaration also solicits information regarding
the nature of the passengers’ visit to the state, including
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Figure 1. Hawaiian Islands. Areas with dengue activity during the
2001–2002 outbreak are marked in red; the number of laboratory-
positive cases is noted adjacent to the island name. *The island of
Hawaii is usually called Big Island to avoid confusion with the state
of Hawaii.proposed destinations and intended length of stay. After
review at the port of entry, the declaration forms are for-
warded to Department of Business and Economic
Development and Tourism for data entry and storage. We
selected the 4 weeks for which the incidence of illness
onset for laboratory-positive dengue infections in Hawaii
was the highest (September 12–October 10, 2001) and
identified 99,766 parties with a declaration who arrived in
Hawaii during that time frame (Figure 2). The person who
completed the form was defined as the “visitor” for our
study. To be eligible for inclusion, visitors had to 1) supply
a complete mailing address within the United States,
excluding Hawaii; 2) be visiting Hawaii, as opposed to an
in-transit layover (<24 hours) to another destination; and
3) express an intention to visit just 1 of the following
islands during their stay—Maui, Oahu, or Hawaii. By sam-
pling visitors who intended to visit only 1 island, we hoped
to reduce the number of respondents reporting multiple
exposures so that any dengue infections identified could be
attributed to a specific island. 
A total of 43,161 (43%) visitors fit the criteria. From
these, a stratified, random sample of 4,000 visitors was
selected: 2,000 visitors to Maui and 1,000 visitors each to
Oahu and Hawaii. (The island of Hawaii is commonly
called the Big Island and is referred to as such for the
remainder of this article to avoid confusion with the state
of Hawaii.) Because most dengue infections identified dur-
ing the outbreak were in residents of Maui, visitors to this
island were oversampled to increase the probability of
detecting dengue infections among travelers. In contrast,
visitors to the Big Island were used as a comparison group
because no dengue infections had been identified from
exposures on that island during the outbreak (Figure 1). 
On December 11, 2001, a questionnaire packet was
mailed to the 4,000 visitors in our sample. The packet con-
tained a letter explaining the purpose of the study, a self-
addressed stamped envelope, and a 14-question survey.
Visitors were asked demographic information, dates of
travel to Hawaii, knowledge of the dengue outbreak,
changes made to vacation plans due to the outbreak,
actions taken to reduce mosquito exposures, which islands
were visited, and specifically whether the visitor had trav-
eled to the Hana, Maui, area. In addition, the questionnaire
asked if the visitor became ill during or up to 14 days after
the trip, and if so, what symptoms were experienced.
Finally, visitors were asked to provide a name, phone num-
ber, or email address so they could be contacted by HDOH. 
Denguelike-illness (DLI) was defined as fever and/or
chills with at least 1 additional symptom, including the fol-
lowing: headache, body aches, eye pain, muscle aches,
joint pain, rash, bleeding gums, blood in the stool, or nose-
bleed. Our description of clinical DLI was intentionally
less restrictive than that used for surveillance by the World
Health Organization (WHO), which uses fever plus 2 other
compatible symptoms. We also allowed a history of chills
to serve as an indicator of fever when no temperature was
taken because we wanted to increase the probability of
identifying any dengue infections that had occurred in vis-
itors (1,10). 
Visitors reporting DLI were contacted. After a brief
description of the outbreak, and risks and benefits of par-
ticipating, they were asked to consent to having blood
drawn for serologic testing. HDOH arranged to have blood
drawn in conjunction with the visitor’s local health depart-
ment, doctor, or diagnostic laboratory at no cost to the
patient. All specimens were tested for anti-dengue
immunoglobulin (Ig) G antibodies at the Division of
Vector-Borne Infectious Diseases, Centers for Diseases
Control and Prevention (CDC), by methods previously
described (11,12). 
Statistical Evaluation 
Statistical analyses were performed by using SAS (ver-
sion 8.2, Cary, NC, USA) and SAS-Callable SUDAAN
release 8.0 (Research Triangle Institute, Research Triangle
Park, NC, USA). Responses were weighted to reflect the
visitor’s port-of-entry (which island they originally flew
into from the mainland) and their intended island destina-
tion; the survey weights were created by SMS Research
and Marketing Services, Inc (Honolulu, HI, USA). In the
following text, numbers are presented unadjusted, fol-
lowed by the weighted percentage unless otherwise noted;
chi-square and relative risks are weighted. 
The incidence of dengue infection among participants
was calculated as the number of visitors who were anti-
dengue IgG positive, divided by the total number of per-
son-days in Hawaii for all those serologically tested. The
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Figure 2. Date if illness onset for 122 laboratory-positive dengue
infections, by 4-week period, Hawaii, May 23, 2001–January 30,
2002. upper 95% confidence limit (CL) for dengue incidence
was calculated on the basis of the Poisson distribution as
Maximum risk = –ln (0.05)/t x (365), where t is the num-
ber of person days of exposure (13,14). The state of
Hawaii’s HDOH Institutional Review Board approved the
study through expedited review on March 12, 2002. 
Results 
A total of 3,064 (77%) visitors responded to the survey
(Figure 3). Respondents were 47% male and 53% female.
The median age was 44 years (range 14–94 years).
Respondents were similar to nonrespondents in terms of
sex and the number of days spent in Hawaii. Most respon-
dents and nonrespondents were 30–59 years of age (69%
and 67%, respectively). 
The median length of stay in Hawaii was 8 days (range
2–188 days). Resort hotels were the most common accom-
modation (60%), followed by condominiums (22%), pri-
vate residences (16%), bed and breakfast hotels (1%), and
campgrounds (0.4%). The distribution of island destina-
tions among respondents is shown in Figure 4. A total of
2,729 (88%) of the respondents visited only the island they
had indicated on the agricultural declaration upon arrival
in Hawaii; 94 (4%) went to the island indicated on the dec-
laration form as well as to other islands; and 241 (8%) vis-
ited an island(s) other than the one indicated on the
declaration. Sixteen percent of all respondents (n = 655)
reported going to Hana, Maui, of whom 74 (12%) stayed
overnight.
Knowledge of the Outbreak
Only 238 (8%) of respondents reported that they knew
about the dengue outbreak before they traveled to Hawaii;
1,467 (45%) learned of it while in Hawaii; 244 (9%) first
heard of it after leaving Hawaii but before receiving the
survey questionnaire, and 1,071 (37%) learned of the out-
break from the HDOH survey. Of the 1,949 (62%) visitors
who knew of the outbreak before receiving the question-
naire packet, >80% first learned of the outbreak from the
news media (newspaper, radio, or television) (Figure 5). 
Of the 1,705 respondents who learned of the outbreak
either before or during their visit to Hawaii, 483 (27%)
took personal precautions to reduce their exposure to mos-
quito bites, and 213 (10%) changed their vacation plans
because of the outbreak. Among those who changed their
plans, 146 (66%) did not travel to Hana, Maui; 73 (35%)
skipped activities such as camping, hiking, or golfing that
they had originally planned; 9 (5%) changed the types of
places they stayed at while in Hawaii; 5 (5%) decided not
to travel to Maui; and 7 (5%) shortened their vacation to
Hawaii. Determining how many deferred coming to
Hawaii because of the dengue outbreak, of course, is not
possible. Of those who took personal precautions to avoid
mosquito bites, 332 (66%) used repellent, 118 (24%) left
places if mosquitoes were seen, 83 (18%) limited their
time outdoors, 80 (17%) wore long pants and long-sleeved
shirts when outdoors, and 38 (9%) used mosquito coils,
sprayed insecticide in or around the places that they
stayed, or both. 
Atotal of 232 (8%) visitors reported becoming ill either
during their trip or within 14 days of leaving Hawaii. The
reported illness in 138 (59%) of the ill respondents did not
meet criteria for DLI (Table). Respondents with illness that
did not meet DLI criteria reported a median of 2 symp-
toms; headache, nausea, and diarrhea were the most fre-
quently reported among this group. 
Ninety-four visitors (3% of all respondents and 43% of
those ill) met criteria for DLI, of which 12 reported at least
1 hemorrhagic manifestation. Respondents with DLI
reported a median of 7 symptoms; chills, headache, body
pain, muscle aches, and fever were each reported by more
than half of respondents with DLI. 
Of visitors with DLI, 38 (40%) became ill while still
vacationing in Hawaii, 34 (36%) became ill 1–10 days
after leaving Hawaii and 16 (18%) became ill 11–14 days
after leaving the islands. The median duration of illness
was 7 days (range 1–60). Thirty-four (34%) of the visitors
with DLI saw a doctor for their illness; in 2 patients,
dengue was diagnosed by their physician, and 2 others
stated that they had been hospitalized, once for suspected
meningitis and once for a respiratory infection. 
The proportion of visitors reporting any illness
(7%–8%) or DLI (3%) was very similar for each of the 3
islands (Oahu, Maui, and the Big Island). Visiting the epi-
center of outbreak, Hana, Maui, was not significantly asso-
DENGUE  RESEARCH
752 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 5, May 2005
Figure 3. Participation rates in the survey and serologic testing to
assess the risk for dengue transmission to visitors during an out-
break in Hawaii, 2001. See text for further details.ciated with reporting DLI. However, staying overnight in
Hana was associated with reporting DLI symptoms when
compared to visitors without illness (relative risk = 2.78,
95% CI 1.04–7.43). The type of accommodation used in
Hawaii (hotel, condominium, bed and breakfast) was not
significantly associated with reporting DLI. 
Nine (9%) of the 94 persons with DLI did not provide
a telephone number or email address for follow-up. Of the
remaining 85 (91%) respondents with DLI, 27 (32%) pro-
vided a serum specimen for testing through their local
department of health or physician; 18 (23%) could not be
contacted after repeated attempts; and 40 (45%) refused
testing or did not show up for their scheduled appointment
to draw blood. 
The 27 visitors who had blood drawn stayed in Hawaii
for a median of 8 days (mean 13 days). The median inter-
val from illness onset to collection of the serum was 224
days (range 153–310). All samples from the 27 persons
were negative for anti-dengue IgG antibodies. These 27
visitors contributed a total of 358 person-days of exposure
during the outbreak; the point estimate of dengue inci-
dence is therefore zero infections per 358 person-days of
exposure (0 per person-year) with an upper 95% CL of 3.0
cases per person-year (unweighted data). 
Discussion 
The state of Hawaii currently receives 5.3 million
domestic and 2.2 million international visitors each year.
In light of this, the recent reemergence of dengue fever in
Hawaii represents a potential threat to populations across
the US mainland and elsewhere. The current study was
undertaken to assess the risk of visitors acquiring dengue
infection during the outbreak. This information is needed
because of the sheer number of visitors and the high like-
lihood that dengue will be reintroduced into Hawaii in the
future. 
Our investigation indicated that the risk for dengue
among domestic travelers to Hawaii during the peak of the
outbreak was low. Although 3% of the visitors surveyed
reported experiencing DLI, none of the persons who
underwent anti-dengue IgG antibody testing had evidence
of dengue infection. The major limitation of this study is
that only approximately one quarter of persons with DLI
provided a serum specimen. However, these persons were
similar to those with DLI who did not provide a specimen
in regard to age, sex, islands visited, and number of days
spent in Hawaii. In addition, the median number of symp-
toms reported by those with DLI who provided a blood
specimen and those who did not was the same for both
groups, and no significant differences were found between
groups with regard to individually reported symptoms. In
aggregate, these data suggest that the results from the sub-
set who provided a specimen for testing may be represen-
tative of all who reported DLI. 
Two additional pieces of information corroborate our
assessment that the risk for dengue to travelers in this out-
break was low. First, we found that the proportion of trav-
elers reporting DLI was the same for visitors to each of 3
islands, Maui, Oahu, and the Big Island. This finding is in
stark contrast to the incidence of dengue infection among
Hawaii residents during the outbreak, where the rates per
100,000 persons were dramatically different, 73, 7, and 0
for Maui, Oahu, and the Big Island, respectively. If DLI
were a specific indicator of dengue infection, one might
have expected the proportion of visitors reporting DLI by
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Figure 4. Island visited for 3,064 survey respondents, by weighted
and unweighted frequencies. Big Island is the term used for the
island of Hawaii to avoid confusion with the state of Hawaii. More
than 1 island could be listed for each respondent, but most visitors
went to only 1 island, that is, 3,384 island visits were reported by
3,064 respondents.
Figure 5. Source of information through which 1,949 visitors to
Hawaii first learned of the dengue outbreak in 2001. HDOH,
Hawaii Department of Health. *Other sources of information
included family, friends, or co-workers who learned of the outbreak
from the media or Internet; signs posted in and around Hana,
Maui; and other tourists or Hawaii residents who informed the
respondent.island to roughly parallel the risk profile observed for
island residents. In other words, the lack of concordance
between the trends in dengue incidence rates among resi-
dents of the various islands during the outbreak and the
proportion of visitors with DLI suggests that the reported
DLI illnesses, including those not evaluated serologically,
were not dengue fever. 
Second, during the outbreak investigation conducted
before this survey, we made a concerted attempt to identi-
fy travelers with dengue with little success. These efforts
included a request to all state epidemiologists to consider
dengue infection among persons returning ill from Hawaii,
communication through CDC’s Epi-X system, and exten-
sive outreach through venues frequented by visitors (car
rental agencies, hotels, tourist information centers). Only 7
(6%) of the 122 persons with laboratory-positive dengue
infection were nonresidents. All 7 nonresidents with
dengue stayed at rental homes in the epicenter of the out-
break (Hana, Maui), and 6 of the 7 had occupied the same
house. Another 70 nonresidents who visited Hawaii during
the outbreak were reported to HDOH by other states as
having possible dengue infections; 30 agreed to be sero-
logically tested—all results were negative. 
The low rate of dengue infections is difficult to attrib-
ute to personal protective measures undertaken by the trav-
elers. More than 40% of the visitors surveyed did not know
about the outbreak until after their vacation had ended. Of
the ≈60% who learned of the outbreak before arriving in
Hawaii or while on vacation, only 26% took personal pre-
cautions to avoid mosquito bites (e.g., using mosquito
repellent) and just 10% changed their activities to reduce
potential exposures. 
While imperfect, the most effective way of alerting
visitors about the outbreak appears to be through the
media, including radio, television, and newspapers.
Among visitors who learned of the outbreak before or dur-
ing their visit, almost 90% stated that they first heard
about it through these channels. Other sources of informa-
tion such as travel agents, Web pages, hotel staff, car
rental agencies, and information centers appear to have
been less informed, but they can still play an important
role in providing important supplemental information.
Since many people on vacation purposefully avoid televi-
sion and newspapers, new strategies should be explored
for increasing the proportion of travelers who can be
reached with important health protection messages if
needed in the future. 
We caution that the low risk for dengue infection
among travelers to Hawaii may not be applicable to other
settings where dengue is endemic, where the predominant
mosquito vector is Ae. aegypti, or when outbreak-associ-
ated attack rates are much higher than that observed in
Hawaii during 2001 to 2002. However, relatively few
studies have attempted to quantify the risk for dengue
infection among short-term travelers, and the data avail-
able from other cohorts encompass a wide range. One
cohort study in Puerto Rico identified no recent dengue
infections in 153 relief workers, and the investigators esti-
mated the upper limit of risk to be 1.7 dengue infections
per person-year exposure (13). A study of Swedish travel-
ers estimated the risk for dengue fever to be highest
among visitors to the Indian subcontinent and the Malay
Peninsula (30–58 infections per 100,000 travelers) (15).
However, another study among Israeli travelers to
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1,000-fold higher (3–5 per 1,000 travelers) (16).
Moreover, a seroconversion rate of 6.7% was reported
among 104 younger Israeli travelers on extended trips
(3–16 months) to the tropics (8). The lack of homogeneity
of these data suggests that factors such as location of trav-
el, the intensity of dengue activity at the time, the length
of stay, and the type of travel engaged in are likely to be
important determinants of the risk for dengue among vis-
itors in any particular setting. 
While a precise estimate of the risk may not be obtain-
able,  >500 laboratory-confirmed and 2,000 suspected
dengue infections reported in returning US travelers from
1986 to 2000 indicate that the risk for infection among vis-
itors to dengue-affected areas is not insignificant (17–22).
In light of this, we recommend that US clinicians consider
the possibility of dengue transmission when evaluating
febrile rash illnesses among travelers to areas with a histo-
ry of dengue activity, including the Pacific Islands.
This study has several limitations. First, as noted above,
only approximately one fourth of all persons reporting DLI
underwent serologic testing. The most frequent reasons for
declining to have blood drawn were inconvenience, an
aversion to needles, or sense that since the illness was in
the past (on average, 7 months before) and had resolved,
testing had little benefit. If we were to conduct this type of
study in the future, we would make a concerted attempt to
shorten the time between departure from Hawaii and fol-
low-up contact. 
A second limitation is that we sought to test only per-
sons who had symptoms compatible with dengue fever;
therefore, our efforts would not have identified infections
that were very atypical in presentation or asymptomatic.
However, we used a fairly inclusive definition of DLI, and
there is no reason to believe the rate of dengue infection
would have been appreciably higher among those who
were asymptomatic as compared to those with compatible
symptoms. Third, illness and exposure histories were self-
reported and therefore potentially subject to recall bias. 
In summary, our findings suggest that the risk for
dengue for travelers to Hawaii during the 2001–2002 out-
break was limited. Given Hawaii’s interconnectedness to
areas of the world with endemic and epidemic dengue,
Hawaii will likely experience another outbreak in the
future. Should that occur, the most effective means cur-
rently available for informing visitors is through the
media; the message to tourists should be that the risk for
dengue infection is likely to be low, but it still exists. 
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